2020
Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case–control study
Shen Y, Risch H, Lu L, Ma X, Irwin ML, Lim JK, Taddei T, Pawlish K, Stroup A, Brown R, Wang Z, Jia W, Wong L, Mayne ST, Yu H. Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case–control study. Cancer Causes & Control 2020, 31: 321-332. PMID: 32060838, PMCID: PMC7136513, DOI: 10.1007/s10552-020-01277-1.Peer-Reviewed Original ResearchConceptsRisk of HCCCase-control studyHepatocellular carcinomaRisk factorsHCV infectionHCC riskOdds ratioHepatitis C virus antibodyUnconditional logistic regression modelsElevated HCC riskRapid case ascertainmentC virus antibodyHeavy alcohol intakeConfidence intervalsFamily cancer historyImportant risk factorRandom digit dialingLow socioeconomic statusUnhealthy lifestyle choicesLower household incomeLogistic regression modelsNSAID useAlcohol intakeCigarette smokingHigher BMI
2019
Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium
Webb PM, Na R, Weiderpass E, Adami HO, Anderson KE, Bertrand KA, Botteri E, Brasky TM, Brinton LA, Chen C, Doherty JA, Lu L, McCann SE, Moysich KB, Olson S, Petruzella S, Palmer JR, Prizment AE, Schairer C, Setiawan VW, Spurdle AB, Trabert B, Wentzensen N, Wilkens L, Yang HP, Yu H, Risch HA, Jordan SJ. Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium. Annals Of Oncology 2019, 30: 310-316. PMID: 30566587, PMCID: PMC6386026, DOI: 10.1093/annonc/mdy541.Peer-Reviewed Original ResearchConceptsNon-aspirin nonsteroidal anti-inflammatory drugsNonsteroidal anti-inflammatory drugsEndometrial Cancer ConsortiumEndometrial cancerAnti-inflammatory drugsObese womenOdds ratioCancer ConsortiumStudy-specific odds ratiosLogistic regressionStandard-dose aspirinUse of aspirinUse of acetaminophenConfidence intervalsTimes/weekCase-control studyRisk of cancerMixed-effects logistic regressionLow-dose formulationsLeast weekly useNormal weightPooled analysisInverse associationStratified analysisReduced risk
2017
Breastfeeding and Endometrial Cancer Risk
Jordan SJ, Na R, Johnatty SE, Wise LA, Adami HO, Brinton LA, Chen C, Cook LS, Dal Maso L, De Vivo I, Freudenheim JL, Friedenreich CM, La Vecchia C, McCann SE, Moysich KB, Lu L, Olson SH, Palmer JR, Petruzella S, Pike MC, Rebbeck TR, Ricceri F, Risch HA, Sacerdote C, Setiawan VW, Sponholtz TR, Shu XO, Spurdle AB, Weiderpass E, Wentzensen N, Yang HP, Yu H, Webb PM. Breastfeeding and Endometrial Cancer Risk. Obstetrics And Gynecology 2017, 129: 1059-1067. PMID: 28486362, PMCID: PMC5473170, DOI: 10.1097/aog.0000000000002057.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskEndometrial cancerCancer riskOdds ratioStudy-specific odds ratiosEndometrial Cancer ConsortiumBody mass indexMultivariable logistic regressionConfidence intervalsCase-control studyMaternal benefitsNulliparous womenHistologic subtypeMass indexCommon cancerLower riskStudy heterogeneityCancer ConsortiumControl groupCancerLogistic regressionAverage durationLonger average durationWomenBreastfeedingAspirin Use and Reduced Risk of Pancreatic Cancer
Risch HA, Lu L, Streicher SA, Wang J, Zhang W, Ni Q, Kidd MS, Yu H, Gao YT. Aspirin Use and Reduced Risk of Pancreatic Cancer. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 68-74. PMID: 27999143, PMCID: PMC5225096, DOI: 10.1158/1055-9965.epi-16-0508.Peer-Reviewed Original ResearchConceptsPancreatic cancerAspirin useRegular useConfidence intervalsLong-term aspirin useControl subjects frequencyLow-dose aspirinAvoidance of smokingBody mass indexPopulation-based studyUnconditional logistic regressionABO blood groupRisk-benefit analysisAspirin typeCagA seropositivityDiabetes mellitusMass indexCigarette smokingCardiovascular diseaseAspirinCancerCertain cancersLogistic regressionBlood groupSubjects frequency
2016
MNGO-11. REPORT FROM THE MENINGIOMA CONSORTIUM: CONFIRMATION OF A MENINGIOMA RISK LOCUS AT 10p12
Claus E, Calvocoressi L, Schildkraut J, Walsh K, Hansen H, Smirnov I, McCoy L, Lu L, Ma X, Bondy M, Wrensch M, Wiemels J. MNGO-11. REPORT FROM THE MENINGIOMA CONSORTIUM: CONFIRMATION OF A MENINGIOMA RISK LOCUS AT 10p12. Neuro-Oncology 2016, 18: vi103-vi103. DOI: 10.1093/neuonc/now212.432.Peer-Reviewed Original ResearchOdds ratioMeningioma riskMeningioma casesPrimary brain tumorsPopulation-based controlsCase/control studyNon-Hispanic CaucasiansAllele odds ratioGenome-wide association studiesKaiser Permanente Research ProgramSpinal cordSuch lesionsBrain tumorsControl studyConfidence intervalsFirst genome-wide association studyMeningiomasTumorsRisk lociUnited StatesSusceptibility lociRisk
2015
Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2)
Yang HP, Cook LS, Weiderpass E, Adami HO, Anderson KE, Cai H, Cerhan JR, Clendenen TV, Felix AS, Friedenreich CM, Garcia-Closas M, Goodman MT, Liang X, Lissowska J, Lu L, Magliocco AM, McCann SE, Moysich KB, Olson SH, Petruzella S, Pike MC, Polidoro S, Ricceri F, Risch HA, Sacerdote C, Setiawan VW, Shu XO, Spurdle AB, Trabert B, Webb PM, Wentzensen N, Xiang YB, Xu Y, Yu H, Zeleniuch-Jacquotte A, Brinton LA. Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). British Journal Of Cancer 2015, 112: 925-933. PMID: 25688738, PMCID: PMC4453954, DOI: 10.1038/bjc.2015.24.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskCancer riskInfertility causesOdds ratioElevated endometrial cancer riskEndometrial cancer risk factorsEndometrial Cancer ConsortiumSelf-reported infertilityAdjusted odds ratioCancer risk factorsConfidence intervalsCase-control studyStudy-specific definitionsParous womenEndometrial cancerNulliparous womenPooled analysisNational registryRisk factorsCancer ConsortiumInfertilityNulliparityInfertility concernsInfertility dataLarger study
2014
Intrauterine devices and endometrial cancer risk: A pooled analysis of the Epidemiology of Endometrial Cancer Consortium
Felix AS, Gaudet MM, La Vecchia C, Nagle CM, Shu XO, Weiderpass E, Adami HO, Beresford S, Bernstein L, Chen C, Cook LS, De Vivo I, Doherty JA, Friedenreich CM, Gapstur SM, Hill D, Horn‐Ross P, Lacey JV, Levi F, Liang X, Lu L, Magliocco A, McCann SE, Negri E, Olson SH, Palmer JR, Patel AV, Petruzella S, Prescott J, Risch HA, Rosenberg L, Sherman ME, Spurdle AB, Webb PM, Wise LA, Xiang Y, Xu W, Yang HP, Yu H, Zeleniuch‐Jacquotte A, Brinton LA. Intrauterine devices and endometrial cancer risk: A pooled analysis of the Epidemiology of Endometrial Cancer Consortium. International Journal Of Cancer 2014, 136: e410-e422. PMID: 25242594, PMCID: PMC4267918, DOI: 10.1002/ijc.29229.Peer-Reviewed Original ResearchConceptsEndometrial Cancer ConsortiumEndometrial cancer riskIntrauterine deviceEC riskPooled analysisCancer riskLast useCancer ConsortiumOlder ageUse of IUDsMultivariable logistic regressionConfidence intervalsPooled odds ratioCase-control studyInert intrauterine deviceDuration of useHeavy bleedingOdds ratioReversible contraceptivesHormonal changesEC casesReduced riskBiologic effectsUterine environmentLogistic regression
2013
Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk
Delahanty RJ, Xiang YB, Spurdle A, Beeghly-Fadiel A, Long J, Thompson D, Tomlinson I, Yu H, Lambrechts D, Dörk T, Goodman MT, Zheng Y, Salvesen HB, Bao PP, Amant F, Beckmann MW, Coenegrachts L, Coosemans A, Dubrowinskaja N, Dunning A, Runnebaum IB, Easton D, Ekici AB, Fasching PA, Halle MK, Hein A, Howarth K, Gorman M, Kaydarova D, Krakstad C, Lose F, Lu L, Lurie G, O'Mara T, Matsuno RK, Pharoah P, Risch H, Corssen M, Trovik J, Turmanov N, Wen W, Lu W, Cai Q, Zheng W, Shu XO. Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers & Prevention 2013, 22: 216-223. PMID: 23221126, PMCID: PMC3677562, DOI: 10.1158/1055-9965.epi-12-0903.Peer-Reviewed Original ResearchMeSH KeywordsAsian PeopleBiomarkers, TumorCase-Control StudiesChinaEndometrial NeoplasmsFemaleFollow-Up StudiesGene Expression ProfilingGenetic Predisposition to DiseaseHumansInflammationLinkage DisequilibriumMiddle AgedNeoplasm StagingOligonucleotide Array Sequence AnalysisPolymorphism, Single NucleotidePrognosisRisk FactorsConceptsEndometrial cancer riskEndometrial cancer casesEndometrial cancerSingle nucleotide polymorphismsOdds ratioCancer casesEndometrial carcinogenesisCancer riskStage IConfidence intervalsInflammation pathway genesInflammatory pathway genesAllelic odds ratioChronic inflammationEpidemiologic evidenceInflammatory pathwaysPathway genesSignificant associationStage IIGenetic susceptibilityMMP9 polymorphismsAdditional studiesCancerGenetic polymorphismsFollow-up genotyping